Article
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
ESMO open - 1 Oct 2021
Planchard D, Feng P-H, Karaseva N, Kim S-W, Kim T M, Lee C K, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, Howarth P, Jänne P A, Kobayashi K
Abstract excerpt
BACKGROUND: The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum-pemetrexed chemotherapy versus osimertinib monotherapy in epidermal growth factor receptor mutation-positive (EGFRm) advanced/metastatic non-small-cell lung cancer (NSCLC). The safety run-in, reported here, assessed the safety and tolerability of osimertinib with chemotherapy prior to...
Topics
Join the communities discussing this publication.